High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 9, 2016, Pages 1004-1013

  Verhaegh, B P M ^a,b   De Vries, F ^a,c   Masclee, A A M ^a,b   Keshavarzian, A ^c,d   De Boer, A ^c   Souverein, P C ^c   Pierik, M J ^a   Jonkers, D M A E ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d RUSH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; DYSBIOSIS; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC COLITIS; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT DURATION; AGED; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; MIDDLE AGED; ODDS RATIO; RISK;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLITIS, MICROSCOPIC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ODDS RATIO; PROTON PUMP INHIBITORS; RISK; SEROTONIN UPTAKE INHIBITORS;

EID: 84960171827     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13583     Document Type: Article

References (50)

1. Magro F, Langner C, Driessen A, et al,. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013; 7: 827-51.
2. Williams JJ, Beck PL, Andrews CN, Hogan DB, Storr MA,. Microscopic colitis-a common cause of diarrhoea in older adults. Age Ageing 2010; 39: 162-8.
3. Bonderup OK, Wigh T, Nielsen GL, Pedersen L, Fenger-Gron M,. The epidemiology of microscopic colitis: a 10-year pathology-based nationwide Danish cohort study. Scand J Gastroenterol 2015; 3: 1-6.
4. Verhaegh BP, Jonkers DM, Driessen A, et al,. Incidence of microscopic colitis in the Netherlands. A nationwide population-based study from 2000 to 2012. Dig Liver Dis 2015; 47: 30-6.
5. Chande N, MacDonald JK, McDonald JW,. Interventions for treating microscopic colitis: a Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group systematic review of randomized trials. Am J Gastroenterol 2009; 104: 235-41; quiz 4, 42.
6. Miehlke S, Madisch A, Voss C, et al,. Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther 2005; 22: 1115-9.
7. Hjortswang H, Tysk C, Bohr J, et al,. Health-related quality of life is impaired in active collagenous colitis. Dig Liver Dis 2011; 43: 102-9.
8. Beaugerie L, Pardi DS,. Review article: drug-induced microscopic colitis-proposal for a scoring system and review of the literature. Aliment Pharmacol Ther 2005; 22: 277-84.
9. Bonderup OK, Fenger-Gron M, Wigh T, Pedersen L, Nielsen GL,. Drug exposure and risk of microscopic colitis: a nationwide Danish case-control study with 5751 cases. Inflamm Bowel Dis 2014; 20: 1702-7.
10. Fernandez-Banares F, Esteve M, Espinos JC, et al,. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol 2007; 102: 324-30.
11. Keszthelyi D, Penders J, Masclee AA, Pierik M,. Is microscopic colitis a drug-induced disease? J Clin Gastroenterol 2012; 46: 811-22.
12. Masclee GM, Coloma PM, Kuipers EJ, Sturkenboom MC,. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol 2015; 110: 749-59.
13. Keszthelyi D, Masclee AA,. Effects of proton pump inhibitor therapy in the distal gut: putting the pieces together. Dig Dis Sci 2012; 57: 2487-9.
14. The Clinical Practice Research Datalink. Available at: http://www.cprd.com/intro.asp (accessed July, 2015).
15. Jick H, Jick SS, Derby LE,. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766-8.
16. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al,. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-9.
17. Richardson DB,. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004; 61: e59.
18. WHO Defined Daily Dose. Available at: http://www.whocc.no/ddd/definition-and-general-considera/ (accessed July, 2015).
19. Greenland S,. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995; 6: 356-65.
20. Capurso G, Marignani M, Attilia F, et al,. Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature. Dig Liver Dis 2011; 43: 380-5.
21. Keszthelyi D, Jansen SV, Schouten GA, et al,. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther 2010; 32: 1124-8.
22. Yu YH, Han DS, Choi EY, et al,. Is use of PPIs related to increased intraepithelial lymphocytes in the colon? Dig Dis Sci 2012; 57: 2669-74.
23. Imhann F, Bonder MJ, Vich Vila A, et al,. Proton pump inhibitors affect the gut microbiome. Gut 2015; doi: 10.1136/gutjnl-2015-310376 [Epub ahead of print].
24. Crowson MS, Shull GE,. Isolation and characterization of a cDNA encoding the putative distal colon H+, K(+)-ATPase. Similarity of deduced amino acid sequence to gastric H+, K(+)-ATPase and Na+, K(+)-ATPase and mRNA expression in distal colon, kidney, and uterus. J Biol Chem 1992; 267: 13740-8.
25. Kunzelmann K, Mall M,. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev 2002; 82: 245-89.
26. Mullin JM, Gabello M, Murray LJ, et al,. Proton pump inhibitors: actions and reactions. Drug Discov Today 2009; 14: 647-60.
27. Shin JM, Sachs G,. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10: 528-34.
28. Riddell RH, Tanaka M, Mazzoleni G,. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. Gut 1992; 33: 683-6.
29. Giardiello FM, Hansen FC 3rd, Lazenby AJ, et al,. Collagenous colitis in setting of nonsteroidal antiinflammatory drugs and antibiotics. Dig Dis Sci 1990; 35: 257-60.
30. Gleeson MH, Davis AJ,. Non-steroidal anti-inflammatory drugs, aspirin and newly diagnosed colitis: a case-control study. Aliment Pharmacol Ther 2003; 17: 817-25.
31. Kitchen PA, Levi AJ, Domizio P, Talbot IC, Forbes A, Price AB,. Microscopic colitis: the tip of the iceberg? Eur J Gastroenterol Hepatol 2002; 14: 1199-204.
32. Wallace JL, Syer S, Denou E, et al,. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-22, 22 e1-5.
33. Petruzzelli M, Vacca M, Moschetta A, et al,. Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts. Clin Biochem 2007; 40: 503-10.
34. Djahanguiri B, Abtahi FS, Hemmati M,. Prevention of aspirin-induced gastric ulceration by bile duct or pylorus ligation in the rat. Gastroenterology 1973; 65: 630-3.
35. Brown PM, Drossman DA, Wood AJ, et al,. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology 2011; 141: 507-16.
36. Ghia JE, Li N, Wang H, et al,. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 2009; 137: 1649-60.
37. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T,. High densities of serotonin and peptide YY cells in the colon of patients with lymphocytic colitis. World J Gastroenterol 2012; 18: 6070-5.
38. Sikander A, Sinha SK, Prasad KK, Rana SV,. Association of serotonin transporter promoter polymorphism (5-HTTLPR) with microscopic colitis and ulcerative colitis. Dig Dis Sci 2015; 60: 887-94.
39. Goldner D, Margolis KG,. Association of Serotonin Transporter Promoter Polymorphism (5HTTLPR) with Microscopic Colitis and Ulcerative Colitis: Time to Be AsSERTive? Dig Dis Sci 2015; 60: 819-21.
40. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD,. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996; 16: 2352-64.
41. Kim DY, Camilleri M,. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95: 2698-709.
42. Aktunc E, Kayhan B, Arasli M, Gun BD, Barut F,. The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis. Immunopharmacol Immunotoxicol 2011; 33: 667-75.
43. Dhamija P, Hota D, Kochhar R, Sachdev A, Chakrabarti A,. Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis. Ind J Gastroenterol 2014; 33: 151-6.
44. Fernandez-Banares F, Casanova MJ, Arguedas Y, et al,. Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish microscopic colitis group. Aliment Pharmacol Ther 2016; 43: 400-26.
45. Chande N, Driman DK, Reynolds RP,. Collagenous colitis and lymphocytic colitis: patient characteristics and clinical presentation. Scand J Gastroenterol 2005; 40: 343-7.
46. Madisch A, Miehlke S, Bartosch F, Bethke B, Stolte M,. Microscopic colitis: clinical presentation, treatment and outcome of 494 patients. Z Gastroenterol 2014; 52: 1062-5.
47. Pilotto A, Franceschi M, Vitale D, et al,. The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. Am J Gastroenterol 2008; 103: 2816-23.
48. Etienney I, Beaugerie L, Viboud C, Flahault A,. Non-steroidal anti-inflammatory drugs as a risk factor for acute diarrhoea: a case crossover study. Gut 2003; 52: 260-3.
49. Thomson AB, Sauve MD, Kassam N, Kamitakahara H,. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16: 2323-30.
50. Shimura S, Hamamoto N, Yoshino N, et al,. Diarrhea caused by proton pump inhibitor administration: comparisons among lansoprazole, rabeprazole, and omeprazole. Curr Ther Res Clin Exp 2012; 73: 112-20.